NR3C2 and hypertensive disorder: Use of SGLT2is, the nonsteroidal mineralocorticoid receptor antagonist finerenone, hypertension medication (defined by anatomic therapeutic chemical codes), and nephrotoxic medication (as listed by Patel and Sapra [33]) was reported by 44, 0, 80, and 83 patients, respectively.